Search Results for "Pain"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pain. Results 801 to 810 of 879 total matches.

Desvenlafaxine for Depression

   
The Medical Letter on Drugs and Therapeutics • May 19, 2008  (Issue 1286)
particularly for treatment of depression in patients with prominent pain complaints. Table 1. SNRIs and SSRIs ...
The FDA has approved the marketing of desvenlafaxine (Pristiq - Wyeth), the main active metabolite of venlafaxine (Effexor, and others - Wyeth), for treatment of major depressive disorder. Venlafaxine, a norepinephrine and serotonin reuptake inhibitor (SNRI), is available generically as an immediate-release tablet. Venlafaxine extended-release capsules (Effexor XR) are scheduled to go off-patent in 2010.
Med Lett Drugs Ther. 2008 May 19;50(1286):37-9 |  Show IntroductionHide Introduction

Dexlansoprazole (Kapidex) for GERD and Erosive Esophagitis

   
The Medical Letter on Drugs and Therapeutics • Mar 23, 2009  (Issue 1308)
with dexlansoprazole than with placebo included diarrhea, abdominal pain, upper respiratory infection, nausea ...
The FDA has approved the proton-pump inhibitor (PPI) dexlansoprazole (Kapidex - Takeda), a delayed release formulation of the R-enantiomer of lansoprazole (Prevacid - Takeda), for treating and maintaining healing of erosive esophagitis and for treatment of heartburn associated with non-erosive gastroesophageal reflux disease (GERD).
Med Lett Drugs Ther. 2009 Mar 23;51(1308):21-2 |  Show IntroductionHide Introduction

Dronedarone (Multaq) for Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • Oct 05, 2009  (Issue 1322)
— Diarrhea, nausea, abdominal pain and vomiting can occur with dronedarone, but unlike amiodarone ...
Dronedarone (Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but has considerable toxicity.
Med Lett Drugs Ther. 2009 Oct 5;51(1322):78-80 |  Show IntroductionHide Introduction

Degarelix (Firmagon) for Prostate Cancer

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 2009  (Issue 1323)
prostate cancer, including increased bone pain due to metastatic disease, urinary obstruction ...
The FDA has approved degarelix (Firmagon - Ferring), a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist, for rapid medical castration of men with advanced prostate cancer. Abarelix (Plenaxis), the first GnRH antagonist approved by the FDA, was withdrawn from the US market because of immediate hypersensitivity reactions.
Med Lett Drugs Ther. 2009 Oct 19;51(1323):82-3 |  Show IntroductionHide Introduction

Ophthalmic Besifloxacin (Besivance)

   
The Medical Letter on Drugs and Therapeutics • Dec 14, 2009  (Issue 1327)
have included blurred vision, eye pain, eye irritation, eye pruritus and headache. Besifloxacin is classified ...
The FDA has approved the fluoroquinolone besifloxacin 0.6% ophthalmic suspension (Besivance - Bausch & Lomb) for treatment of bacterial conjunctivitis caused by susceptible bacteria. According to the manufacturer, this product was developed specifically for ophthalmic use in a specialized vehicle designed to prolong contact time on the ocular surface. Besifloxacin is not available for systemic use.
Med Lett Drugs Ther. 2009 Dec 14;51(1327):101-3 |  Show IntroductionHide Introduction

A New Conjugate Meningococcal Vaccine (Menveo)

   
The Medical Letter on Drugs and Therapeutics • Jul 26, 2010  (Issue 1343)
disease. 1 ADVERSE EFFECTS — The most common adverse reactions to Menveo have been injection site pain ...
The FDA has approved Menveo (Novartis), a new quadrivalent conjugated polysaccharide vaccine, for protection against disease caused by Neisseria meningitidis in people 11-55 years old.
Med Lett Drugs Ther. 2010 Jul 26;52(1343):59-60 |  Show IntroductionHide Introduction

Colonoscopy Preparations

   
The Medical Letter on Drugs and Therapeutics • Jan 21, 2013  (Issue 1408)
, vomiting, bloating and abdominal pain can occur. Since these preparations may cause electrolyte ...
Colonoscopy remains the preferred method of colorectal cancer screening. Many patients consider cleansing the bowel in preparation for colonoscopy the most unpleasant part of the procedure, but inadequate bowel preparation significantly lowers the diagnostic yield.
Med Lett Drugs Ther. 2013 Jan 21;55(1408):6-7 |  Show IntroductionHide Introduction

Glycopyrrolate/Formoterol (Bevespi Aerosphere) for COPD

   
The Medical Letter on Drugs and Therapeutics • Oct 10, 2016  (Issue 1505)
of inhaled beta2-adrenergic agonists include palpitations, tachycardia, chest pain, tremor, nervousness ...
The FDA has approved a fixed-dose combination of the long-acting anticholinergic glycopyrrolate and the long-acting beta2-adrenergic agonist (LABA) formoterol (Bevespi Aerosphere – AstraZeneca) for long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Glycopyrrolate/formoterol is the fourth long-acting anticholinergic/LABA combination to be approved in the US, but the first to become available in a metered-dose inhaler. Glycopyrrolate/indacaterol (Utibron Neohaler), umeclidinium/vilanterol (Anoro Ellipta), and tiotropium/olodaterol (Stiolto...
Med Lett Drugs Ther. 2016 Oct 10;58(1505):130-2 |  Show IntroductionHide Introduction

Jornay PM - Evening-Dosed Methylphenidate for ADHD

   
The Medical Letter on Drugs and Therapeutics • Aug 12, 2019  (Issue 1578)
, abdominal pain, anxiety, nervousness, restlessness, agitation, irritability, tics, dizziness, vertigo ...
The FDA has approved Jornay PM (Ironshore), a capsule formulation of methylphenidate with a delayed-release outer layer and an extended-release inner layer, for once-nightly treatment of attention-deficit hyperactivity disorder (ADHD) in patients >6 years old. Jornay PM is the first methylphenidate product to become available in the US that is taken in the evening; other long-acting methylphenidate formulations are taken in the morning. It is being marketed specifically for patients who have disruptive ADHD symptoms in the morning.
Med Lett Drugs Ther. 2019 Aug 12;61(1578):126-8 |  Show IntroductionHide Introduction

Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020  (Issue 1611)
, nausea, fatigue, stomatitis, decreased appetite, abdominal pain, and rash can also occur. DRUG ...
The FDA has approved two new drugs for treatment of previously-treated unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki (Enhertu – Daiichi-Sankyo/AstraZeneca), an IV HER2-directed monoclonal antibody linked to the topoisomerase I inhibitor DXd, and tucatinib (Tukysa – Seagen), an oral tyrosine kinase inhibitor.
Med Lett Drugs Ther. 2020 Nov 16;62(1611):182-4 |  Show IntroductionHide Introduction